Melatonin and Heart Attack Risk: What the Data Show
Melatonin is a hormone that regulates sleep-wake cycles and is widely used as a supplement for insomnia and jet lag. Observational studies and meta-analyses have examined whether melatonin use is associated with a higher risk of heart attack, with mixed results. A 2024 umbrella review of randomized trials found no statistically significant increase in major adverse cardiovascular events, including myocardial infarction, in adults taking melatonin at typical doses of 0.5 to 5 mg. However, some cohort analyses note a modest signal for palpitations and slight blood pressure changes in sensitive subgroups, which may prompt further evaluation by clinicians.
Regulatory agencies such as the U.S. Food and Drug Administration classify melatonin as a dietary supplement, not a drug, so premarket safety and efficacy reviews are limited. The American Heart Association and European Society of Cardiology do not list melatonin as a proven cardiovascular risk factor, but they advise caution for patients with existing heart failure, arrhythmias, or recent heart attack. Healthcare providers often weigh individual risk profiles, concomitant medications, and supplement quality before recommending melatonin, especially when patients report chest pain, shortness of breath, or syncope.
Companies, Products, and Market Trends in Melatonin Supplements
Major retailers and supplement companies, including Amazon, Walmart, and CVS Health, sell melatonin gummies, tablets, and liquids, with many products labeled as third-party tested for purity. NSF International, USP, and ConsumerLab provide quality certifications that help consumers identify products meeting label claims for identity, potency, and contaminants. In 2024, the global melatonin supplement market was estimated at over $10 billion, with strong growth driven by e-commerce channels and increased consumer interest in sleep support amid high-stress economic environments.
Some companies have voluntarily reformulated products after independent testing revealed melatonin content deviating significantly from labels, sometimes by more than 400 percent. The Council for Responsible Nutrition and the Consumer Healthcare Products Association issue guidance on labeling transparency and dosage limits, while the Federal Trade Commission monitors advertising claims about heart health and sleep benefits. Investors tracking the nutraceutical sector monitor FDA warning letters, class-action lawsuits, and recalls as key indicators of regulatory and reputational risk for supplement brands.
Heart Attack Symptoms, Emergency Response, and Supplement Safety
Heart attack symptoms include chest discomfort, pain radiating to the arm or jaw, shortness of breath, nausea, and lightheadedness, and immediate medical attention is critical. Melatonin is not a recognized treatment for acute coronary syndrome, and patients should not delay calling emergency services or taking prescribed cardiac medications in favor of supplements. The American College of Cardiology emphasizes rapid activation of emergency medical services, as timely reperfusion therapy significantly reduces mortality and long-term cardiac damage.
For consumers considering melatonin, the National Institutes of Health Office of Dietary Supplements provides fact sheets on dosage, interactions, and side effects, noting that high doses may cause daytime drowsiness and hormonal effects. People on anticoagulants, antiplatelet drugs, or blood pressure medications should consult a physician before use, because melatonin may modulate vascular tone and platelet aggregation in some studies. Trusted resources such as the Mayo Clinic and the AHA offer searchable databases on supplement safety and cardiovascular risk factors to support informed decision-making.